Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. OpGen, Inc.
  6. News
  7. Summary
    OPGN   US68373L3078

OPGEN, INC.

(OPGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

OpGen : Corporate Presentation (PDF)

08/13/2021 | 07:42am EDT

OpGen

Corporate Overview

August 13, 2021

OpGen, Inc.

Forward Looking Statements Disclaimer

This presentation contains forward-looking statements that are subject to many risks and uncertainties. These statements, among other things, relate to our business strategy, goals and expectations concerning our products, future operations, prospects, plans and objectives of management. The words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will" and similar terms and phrases are used to identify forward-looking statements in this presentation. These statements and other statements regarding our future plans constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1955. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond OpGen's control, and that may cause results to differ materially from expectations.

Factors that could cause results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and service offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the fact that we may not effectively use proceeds from recent financings, including our February 2021 and November 2020 financings, and March 2021 warrant exercise and exchange, the realization of expected synergies from our business combination transaction with Curetis GmbH, the successful integration of our company with the operations and business of Curetis GmbH and its subsidiaries and the implementation of the combined company's strategic and business goals and objectives, the impact of COVID-19 on our operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, the ability to comply with the complexities of operating a global business, the success of our commercialization efforts, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this presentation and speak only as of the date of this presentation. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

OpGen, Inc.

2

OpGen Overview

Striving to innovate molecular microbiology

Fast

Comprehensive

Smart

Easy

Rapid Pathogen

Broad Pathogen &

AI-Powered AMR

Sample-To-Answer

Detection For Life

Antimicrobial

Prediction &

Platforms

Threatening Infections

Resistance (AMR)

Bioinformatics

Marker Coverage

OpGen, Inc.

3

OpGen's combined portfolio

Synergistic products and capabilities

Unyvero Platform &

Acuitas Panel &

Global Commercial

Ares Genetics NGS &

Syndromic Tests

Lighthouse

Presence

Bioninformatics

FDA-cleared LRT & LRT BAL for

Acuitas AMR Gene Panel for

Direct sales and marketing in the

lower respiratory tract infections

Isolates pending FDA clearance

U.S.

5 CE-IVD tests

Enhances targeted antibiotic

EMEA, APAC, Latin America and

Unyvero A30 RQ platform in

decision making

China distribution with partners

Lighthouse knowledge base

advanced stages of development

deployed for public health use

OpGen, Inc.

AI-powered AMR prediction combining ARESdb with NGS

Strategic partnerships and collaborations with globally leading IVD & pharma companies

4

OpGen's strategic positioning and benefits

Well positioned to capitalize on global opportunities in infectious disease and rapid AMR detection Proprietary molecular diagnostic tests and platforms

Premier AI-powered bioinformatics solutions for multi-drug resistance diagnostics

Global commercial channel capabilities & partners

Financial leverage, operational synergies, and positive growth-driven business outlook

OpGen, Inc.

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

OpGen Inc. published this content on 13 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 August 2021 11:41:12 UTC.


ę Publicnow 2021
All news about OPGEN, INC.
10/15OPGEN : Announces $15 Million Registered Direct Offering - Form 8-K
PU
10/15OPGEN INC : Entry into a Material Definitive Agreement, Material Modification to Rights of..
AQ
10/14OPGEN : Launches $15 Million Registered Direct Offering
MT
10/14OPGEN : Announces $15 Million Registered Direct Offering
AQ
10/08OPGEN : Corporate Presentation (PDF)
PU
10/04Wall Street Set for Losses, Supply Chain Woes Dent Sentiment
MT
10/04Health Care Stocks Trade Lower Pre-Bell Monday
MT
10/04OPGEN : Health Care
MT
10/04OPGEN : Receives FDA Clearance for Launch of Acuitas AMR Gene Panel; Provides Preliminary ..
MT
10/04OPGEN : Corporate Presentation (PDF)
PU
More news
Analyst Recommendations on OPGEN, INC.
More recommendations
Financials (USD)
Sales 2021 3,90 M - -
Net income 2021 -38,4 M - -
Net Debt 2021 7,16 M - -
P/E ratio 2021 -1,92x
Yield 2021 -
Capitalization 77,7 M 77,7 M -
EV / Sales 2021 21,8x
EV / Sales 2022 8,26x
Nbr of Employees 102
Free-Float 99,8%
Chart OPGEN, INC.
Duration : Period :
OpGen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPGEN, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 2,03 $
Average target price 5,00 $
Spread / Average Target 146%
EPS Revisions
Managers and Directors
Oliver Schacht Chief Executive Officer & Director
William E. Rhodes Non-Executive Chairman
Vadim Sapiro Chief Information Officer
Faranak Atrzadeh Chief Marketing & Scientific Affairs Officer
Johannes Bacher Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
OPGEN, INC.-0.49%78
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414